📇 Rhumatologue · BESANCON CEDEX · (25) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
15 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
118.3 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
19
19 articles ont été cités au moins 19fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 236
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
65
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
26
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Universitaire de Besançon
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial
2025ArticleJournal of Hepatology
Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial
2025ArticleThe Lancet Gastroenterology & Hepatology
SAT-374-YI Health related quality of life in patients with porto-sinusoidal vascular disorder
2025ArticleJournal of Hepatology
Improved survival in patients with refractory variceal bleeding treated with esophageal stents: A multicenter cohort study
2025ArticleJhep Reports
Preemptive tips: the new standard for gastric variceal bleeding in patients with cirrhosis ? Results of a large multicenter randomized controlled trial
2024ArticleHepatology
Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case–control study
2023ArticleJHEP Reports Innovation in Hepatology
Current prognosis of gastric variceal bleeding in France: preliminary results from a multicenter prospective cohort of 87 cirrhotic patients
2023ArticleJournal of Hepatology
Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study
2022ArticlePLoS ONE
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHU JEAN MINJOZ BESANCON
3 BD FLEMING, 25030 BESANCON CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Hepatology (Baltimore, Md.) · 2011
Response-guided pegylated interferon (peg-IFN) plus ribavirin (P/R) therapy trials on genotype (G)1 and G2/G3 hepatitis C virus–infected patients provide contradictory results. We conducted meta-analyses of randomized, controlled trials to address (1) the benefit of a 72-week extended-duration therapy in G1-slow responders and (2) adequate shortened duration therapy in G1 and G2/G3-rapid responders. Seventeen trials were selected, including 624 G1 rapid responders, 570 G1 slow responders, and 2,062 G2/G3 rapid responders. Virologic outcomes and treatment discontinuation data were collected from published articles and by asking investigators. Pooled estimates of sustained virologic response (SVR), relapse, and dropouts were calculated using the random effects model, considering the variability of shortened duration, ribavirin dose, genotype, and baseline viral load. In G1 slow responders, a 72-week extended duration increased SVR (+10.7%; 95% CI [confidence interval]: +4.4% to + 17.1%), decreased relapse (−12.3%; 95% CI: −25.4% to 0%), and did not significantly increase drop-out rates (+4.5%; 95% CI: −0.6% to + 9.6%). The benefit of extended duration was lower when using a weight-based ribavirin regimen (+8.7%; 95% CI: +1.7% to + 15.8%). In G1 rapid responders, a 24-week shortened duration decreased SVR (−12.5%; 95% CI: −19.2% to −5.8%) and increased relapse rates (+8.8%; 95% CI: +2.9% to + 14.8%). Such differences were not significant in patients with baseline viral load <400,000 UL/mL (−4.4%; 95% CI: −9.8% to + 1%). In G2/G3 rapid responders, SVR was more common for standard 24-week duration than for shortened durations (+4.1%; 95% CI: +0.1% to + 8.5), but this benefit was not significant when ribavirin was weight-adjusted and the short duration was 16 weeks (−1.7%; 95% CI: −6.1% to + 2.7%) and for G2 patients (+1.6%; 95% CI: −0.2% to + 5.5%). Conclusion: Long durations of P/R therapy improve SVR, regardless of genotype. This effect is nonetheless negligible in rapid responders, with the most favorable conditions for SVR (G2, G1 with low viral load, and G3 with weight-adjusted ribavirin regimen). (HEPATOLOGY 2011;)
Molecular genetics and metabolism · 2013
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
PloS one · 2022 · Journal Article
Thévenot T, Vendeville S, Weil D, Akkouche L, et al.
American journal of hematology · 2022 · Journal Article
Plessier A, Esposito-Farèse M, Baiges A, Shukla A, et al.
Journal of hepatology · 2022 · Journal Article
De Broucker C, Plessier A, Ollivier-Hourmand I, Dharancy S, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2018 · Journal Article
Ollivier-Hourmand I, Allaire M, Goutte N, Morello R, et al.
European journal of gastroenterology & hepatology · 2016 · Comparative Study
Cervoni JP, Amorós À, Bañares R, Luis Montero J, et al.
Molecular genetics and metabolism · 2013 · Case Reports
Brassier A, Ottolenghi C, Boutron A, Bertrand AM, et al.
Gastroenterology · 2002 · Journal Article
Moreau R, Durand F, Poynard T, Duhamel C, et al.
Journal of hepatology · 2025 · Journal Article
Thévenot T, Elkrief L, Bureau C, Bardou-Jacquet E, et al.
The lancet. Gastroenterology & hepatology · 2025 · Journal Article
Cervoni JP, Weil D, Desmarets M, Lannes A, et al.
Clinics and research in hepatology and gastroenterology · 2022 · Case Reports
Clément M, Cervoni JP, Renosi F, Thévenot T, et al.
Clinics and research in hepatology and gastroenterology · 2020 · Case Reports
Hedjoudje A, Cervoni JP, Patry C, Chatot M, et al.
Clinics and research in hepatology and gastroenterology · 2020 · Journal Article
Cervoni JP, Alby-Lepresle B, Weil D, Zhong P, et al.
JHEP reports : innovation in hepatology · 2025 · Journal Article
Weil D, Clément M, Bouzbib C, Cervoni JP, et al.
MOESM6 of Prognosis of cirrhotic patients admitted to the general ICU
Additional file 6. Figure S3 Log rank test comparing each strata of the new prognostic score with each other strata.
MOESM3 of Prognosis of cirrhotic patients admitted to the general ICU
Additional file 3. Figure S1 Estimated probability of survival of 218 cirrhotic patients admitted to the ICU.
MOESM3 of Prognosis of cirrhotic patients admitted to the general ICU
Additional file 3. Figure S1 Estimated probability of survival of 218 cirrhotic patients admitted to the ICU.
MOESM4 of Prognosis of cirrhotic patients admitted to the general ICU
Additional file 4. Figure S2 Outcome of the studied population. Of the 115 patients who survived their ICU stay, 48 were theoritically eligible for liver transplantation, but only 8 underwent liver transplantation.
MOESM4 of Prognosis of cirrhotic patients admitted to the general ICU
Additional file 4. Figure S2 Outcome of the studied population. Of the 115 patients who survived their ICU stay, 48 were theoritically eligible for liver transplantation, but only 8 underwent liver transplantation.
Prognosis of cirrhotic patients admitted to the general ICU
Abstract Background The prognosis of cirrhotic patients admitted to the ICU is considered to be poor but has been mainly reported in liver ICU. We aimed to describe the prognosis of cirrhotic patients admitted to a gener
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Hepatology (Baltimore, Md.) · 2011 · Journal Article
Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, et al.
European journal of gastroenterology & hepatology · 2010 · Journal Article
Fein F, Weber A, Koch S, Festou N, et al.